Missing child found in critical condition in Mississauga
Officers told CBC Toronto they responded to a call for a missing young child in the area of Mississauga Road and Dundas Street just after 3:30 p.m.
In a post to X, police said the child had "wandered off" but was located by first responders.
Peel paramedics said they attended the scene alongside police and Mississauga Fire for reports of a person in the water, and transported one paediatric patient in critical, life-threatening condition to a local hospital.
Police are asking the public to avoid the Erindale Park area.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Microbix Launches QUANTDx™ Characterized Reference Materials
New Product Line Supporting Diagnostic Assay Manufacturers MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development and validation of diagnostic assays. QUANTDx is being launched at ADLM 2025, the conference of the Association for Diagnostic & Laboratory Medicine being held in Chicago, USA July 28-31, at which Microbix is exhibiting. The QUANTDx product line features accurately-quantified and fully-traceable reference materials that enable assay developers to establish key analytical performance metrics — such as LoD (limit of detection), Sensitivity (positive accuracy), and Specificity (negative accuracy) — that are essential for regulatory submissions and validation. The initial QUANTDx launch includes over 80 such reference materials that cover six of the most commonly tested disease panels, namely the following types of infections — fungal, human papillomaviruses, gastrointestinal, meningitis, respiratory, and sexually-transmitted. This comprehensive product line addresses a critical need within the infectious disease diagnostics industry for high-quality, reliable, and standardized reference materials. QUANTDx complements Microbix's established Quality Assessment Products (QAPs™) portfolio, which includes the industry-recognized PROCEEDx™ (RUO) and REDx™ Controls (IVD) products. Together, these product lines address a broad spectrum of quality-related needs across the diagnostic development lifecycle—from assay design, validation, and quality release through to end-user training and ongoing quality control. This holistic support reinforces Microbix's role as a trusted partner to the global diagnostics industry. Cameron Groome, CEO & President of Microbix, commented, 'The launch of QUANTDx represents a strategic expansion of our capabilities to serve assay developers and clinical laboratories. By leveraging our in-house portfolio of organisms and expertise in nucleic acid quantification, we are confident in delivering reliable and reproducible reference materials to streamline assay development and validation.' Phil Casselli, SVP of Sales and Business Development at Microbix, added, 'We are thrilled by the support we've received from prospective customers for QUANTDx. It's clear that there is strong, unmet demand for high-quality, and fully-quantified reference materials across the diagnostics industry. We believe this launch will provide Microbix with more opportunities to support assay developers, clinical labs, and manufacturers worldwide. We fully expect QUANTDx™ to drive revenue growth and expand our global customer base.' Further information about QUANTDx is available at while purchase enquiries for QUANTDx can be e-mailed to About Microbix Biosystems Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking InformationThis news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of the QUANTDx product line or its relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information except as required by applicable law. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Cameron Groome, CEO(905) 361-8910 Jim Currie, CFO(905) 361-8910 Deborah Honig, Investor RelationsAdelaide Capital Markets(647) 203-8793 ir@ Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM®, Kinlytic®, PROCEEDx™, QAPs™, QUANTDx™, and REDx™ are trademarks of Microbix Biosystems in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
11 minutes ago
- Wall Street Journal
Baseball's ‘Spot-Fixing' Investigation Now Includes a Star Closer
When former Toronto Raptors forward Jontay Porter was caught 16 months ago conspiring with bettors to fix his performance in NBA games, it was easy to believe it was an isolated incident. But the steady drip of revelations since then has shined a spotlight on a frightening reality for the entire industry of professional sports: No caliber of athlete, no matter how rich, famous or talented, is immune to the threat of gambling.
Yahoo
38 minutes ago
- Yahoo
Creyos Featured in Alzheimer's Research at AAIC 2025
Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital testing, and uncovering markers of cognitive resilience. Used in over 400 peer-reviewed studies, Creyos continues to power cutting-edge brain health research around the world. TORONTO, July 29, 2025 /PRNewswire/ -- Creyos, the digital platform trusted by clinicians and researchers to assess brain health with precision and ease, was featured in three independent research presentations at the 2025 Alzheimer's Association International Conference (AAIC). The studies demonstrate how Creyos is helping researchers advance the science of early detection, understand risk, and explore what protects cognitive health as we age. Built on more than 30 years of neuroscience research and validated in over 400 peer-reviewed studies, Creyos enables fast, reliable measurement of key cognitive domains—including memory, attention, reasoning, and executive function. For decades, leading research institutions have leveraged the platform to explore large-scale questions that demand high-quality, scientifically reliable data, with three notable studies chosen for presentation at AAIC this year. "Creyos wasn't born in a boardroom—it came out of necessity in the lab," said Adrian Owen, Professor of Cognitive Neuroscience and Imaging at the University of Western Ontario, Chief Scientific Officer at Creyos, and co-author of one of the featured AAIC posters. "It started as a way to solve a problem I faced in my own research—how to measure cognition in a way that's both rigorous and scalable. Since then, it's been used by hundreds of colleagues around the world, contributing to a growing body of work aimed at understanding cognitive health. It's rewarding to see the role it's playing in advancing research across the field." Highlights from AAIC presentations included: 1. Early Screening Through Digital TasksWestern University – Adrian Owen, PhDUsing data from over 4,000 older adults, researchers applied machine learning to identify the two most predictive Creyos tasks for detecting age-related cognitive impairment. A screener using attention and working memory tasks matched mild cognitive impairment rates in a validation sample of over 9,000 adults, and correctly identified 100% of 14 participants with a clinical Alzheimer's disease diagnosis. The study positions Creyos as a powerful digital alternative to traditional dementia screening tools. 2. Genetics, Risk, and Online Testing in the PISA StudyQIMR Berghofer – Michelle Lupton, PhDThis study, conducted within the Prospective Imaging Study of Aging (PISA)—one of the world's largest cohorts focused on early Alzheimer's detection—validated the use of the Creyos platform for online cognitive testing in adults aged 42–75. Researchers compared self-administered Creyos assessments with traditional in-person testing and MRI-derived brain morphology measures. Findings showed strong alignment between online and in-person results, including associations with Alzheimer's-related brain changes and genetic risk. The study underscores the potential of online cognitive testing as a scalable, cost-effective tool for early detection and large-scale research in Alzheimer's disease. 3. Cognitive Resilience in Aging AdultsRotman Research Institute – Brian Levine, PhDWhy do some people maintain cognitive function despite age-related pathology or trauma? This study used Creyos to assess over 3,300 individuals across three cohorts. The Grammatical Reasoning task emerged as a potential marker of resilience—strong performance was associated with less excessive reliance on episodic memory strategies and greater resilience following PTSD. These insights point to reasoning ability as a potential buffer against cognitive decline. These studies demonstrate that Creyos is no stranger to rigorous science. The platform's role in the research being showcased at AAIC reflects not only continued trust among the global scientific community but also growing momentum in how cognitive data can support early detection, care planning, and treatment across settings. Creyos is used by healthcare providers in primary care, neurology, and behavioral health to screen for cognitive impairment, monitor longitudinal change, and inform care decisions. With nearly 20 million assessments completed and more than 10,000 providers actively using the platform, Creyos is reshaping how brain health is measured, bridging the gap between research insights and real-world care. About Creyos Creyos, formerly known as Cambridge Brain Sciences, is a pioneering healthcare technology company dedicated to transforming how healthcare providers assess and manage patient brain health. Supporting clinicians and health systems worldwide, the Creyos platform includes objective online tasks, digital behavioral health screeners, and condition-specific assessments that deliver actionable insights, promote early intervention, and enable evidence-based clinical decisions for various cognitive and behavioral health conditions, including dementia, ADHD, depression, anxiety, and others. Backed by 30 years of research and a normative database of over 85,000 participants, the FDA-registered Creyos platform has been published in over 400 peer reviewed studies and is recognized as a scientifically-validated solution for measuring and monitoring patient brain health. For more information about Creyos visit Media Contactcreyos@ View original content to download multimedia: SOURCE Creyos Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
